文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒特殊人群用药

低白蛋白血症中丙戊酸与苯妥英毒性监测的回顾性队列研究

Monitoring for valproate and phenytoin toxicity in hypoalbuminaemia: A retrospective cohort study.
PubMed 文献 · Br J Clin Pharmacol · 2021-05-04

该回顾性队列研究评估低白蛋白血症及白蛋白校正总浓度与苯妥英和丙戊酸浓度依赖性毒性的关联。苯妥英校正浓度>20 mg L-1与神经毒性增加相关,丙戊酸低白蛋白血症及校正浓度>100 mg L-1均与神经毒性增加相关,校正方程有助于识别需进一步评估的高危患者。

要点

  • 苯妥英白蛋白校正浓度>20 mg L-1与神经不良反应增加独立相关(OR 1.06)。
  • 丙戊酸低白蛋白血症和校正浓度>100 mg L-1均与神经毒性增加相关。
  • 低白蛋白血症时校正方程可辅助识别需进一步评估毒性风险的患者。

核心结论

  • 低白蛋白血症时白蛋白校正方程有助于识别需进一步评估浓度依赖性毒性的脆弱患者。

研究设计与样本

  • 回顾性队列研究,纳入2018年1月至12月进行苯妥英或丙戊酸浓度监测的患者,数据来自中心实验室数据库和病历。

主要发现

  • 144例苯妥英监测患者中59例(41%)存在低白蛋白血症(≤30 g L-1),校正浓度>20 mg L-1与神经不良反应增加相关(77% vs. 43%,P < .001)。
  • 逻辑回归显示较高白蛋白校正苯妥英浓度为神经毒性独立危险因素(OR 1.06,95% CI 1.01-1.12,P = .011)。
  • 383例丙戊酸监测患者中53例(14%)存在低白蛋白血症,低白蛋白血症(42% vs. 28%,P = .039)和校正浓度>100 mg L-1(49% vs. 23%,P < .001)均与神经毒性增加相关。
  • 多因素逻辑回归显示丙戊酸日剂量(aOR = 1.01,95% CI 1.00-1.02,P = .006)和校正浓度(aOR 1.01,95% CI 1.00-1.02,P = .033)为神经毒性独立危险因素。

临床怎么用

  • 低白蛋白血症患者监测苯妥英或丙戊酸时,可计算白蛋白校正总浓度以辅助识别神经毒性高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Equations to calculate albumin-adjusted total concentrations have been validated to correlate with measured free concentrations for both phenytoin and valproate, but there is a lack of data to assess correlation with clinical outcomes. We aimed to assess the association of hypoalbuminaemia and albumin-adjusted total concentrations with concentration-dependent toxicity for phenytoin and valproate and review the impact on management decisions following concentration monitoring in hypoalbuminaemia. METHODS: Patients undergoing concentration monitoring for phenytoin or valproate between January and December 2018 were included. Patients were identified using a centralised laboratory database with data extracted from medical records. RESULTS: Total phenytoin concentrations were measured for 144 patients, with hypoalbuminaemia (≤30 g L-1 ) recorded in 59 (41%) patients. Albumin-adjusted phenytoin concentration >20 mg L-1 was associated with increased neurological adverse effects (77% vs. 43%, P < .001). On logistic regression, higher albumin-adjusted phenytoin concentration was an independent risk factor for neurotoxicity (OR 1.06, 95% CI 1.01-1.12, P = .011). Total valproate concentrations were measured for 383 patients, with hypoalbuminaemia (≤30 g L-1 ) noted in 53 (14%) patients. For the valproate cohort, hypoalbuminaemia (42% vs. 28%, P = .039) and albumin-adjusted valproate concentration >100 mg L-1 (49% vs. 23%, P < .001) were both associated with increased neurotoxicity. On multiple logistic-regression, valproate daily dose (aOR = 1.01, 95% CI 1.00-1.02, P = .006) and albumin-adjusted valproate concentration (aOR 1.01, 95% CI 1.00-1.02, P = .033) were independent risk factors for neurotoxicity after accounting for confounders. CONCLUSION: While measuring free drug concentrations in hypoalbuminaemia would be ideal, the adjustment equations can help identify vulnerable patients needing further assessment of potential concentration-dependent toxicity.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Madan A, Donovan PJ, Risetto T, et al. Monitoring for valproate and phenytoin toxicity in hypoalbuminaemia: A retrospective cohort study. Br J Clin Pharmacol. 2021. PMID: 33835518. doi:10.1111/bcp.14853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。